Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 06 - 10 entities : Bristol-myers squibb company save search
Bristol Myers Squibb and GRYT Health Evolve Virtual Patient Advocacy Experience
Published: 2021-06-10 (Crawled : 21:00) - biospace.com/
BMY | $48.76 -0.47% 3.9M
|
Health Technology
|
| O: 0.23%
H: 3.28%
C: 2.81%
health
Bristol Myers Squibb Announces Positive Topline Results from Phase 3 TRANSFORM Trial Evaluating Breyanzi (lisocabtagene maraleucel)
Published: 2021-06-10 (Crawled : 12:00) - biospace.com/
BMY | $48.76 -0.47% 3.9M
|
Health Technology
|
| O: 0.23%
H: 3.28%
C: 2.81%
positive results topline phase 3 trial
Harvard's Wyss Institute initiates industry partnership to facilitate brain-targeted drug delivery
Published: 2021-06-10 (Crawled : 12:00) - biospace.com/
BMY | $48.76 -0.47% 3.9M
|
Health Technology
|
| O: 0.23%
H: 3.28%
C: 2.81%
partnership drug drug delivery liver train
Bristol Myers Squibb to Report Results for Second Quarter 2021 on July 28, 2021
Published: 2021-06-10 (Crawled : 12:00) - biospace.com/
BMY | $48.76 -0.47% 3.9M
|
Health Technology
|
| O: 0.23%
H: 3.28%
C: 2.81%
results
FDA approves nivolumab in combination with chemotherapy for metastatic gastric cancer and esophageal adenocarcinoma
Published: 2021-06-10 (Crawled : 10:43) - fda.gov
BMY | $48.76 -0.47% 3.9M
|
Health Technology
|
| O: 0.23%
H: 3.28%
C: 2.81%
cancer fda fda approval nivolumab
Gainers vs Losers
| 54% | 46% |
Top 10 Gainers
CSSE 4 | $0.3499 129.74% 150M
|
Consumer Services
CZOO | $11.04 121.24% 9.6M
|
BOF | $2.05 75.21% 78M
|
AMST | $3.2 60.0% 63M
|
Technology Services
LICN | $0.8592 53.43% 13M
|
WIMI | $1.05 44.75% 13M
|
Technology Services
TROO | $1.51 38.53% 5.6M
|
Manufacturing
MULN | News | $3.675 34.62% 11M
|
Information
RILY | $27.91 28.5% 8.9M
|
Finance
WHLM | $6.43 26.58% 580K
|
Commercial Services
Your saved searches
Save your searches and get alerts when important news are released.